Captor Therapeutics (CTX) Corporate presentation summary

Leadership and expertise

• Leadership team includes experienced professionals with backgrounds in drug discovery, clinical development, and finance, with prior roles at Novartis, AstraZeneca, Roche, and Lilly.

• Founders and executives hold advanced degrees and have significant experience in oncology and targeted protein degradation.

Technology and platform

• Optigrade™ platform enables discovery of molecular glues, bifunctional degraders, and novel E3 ligases for targeted protein degradation.

• LiLis™ program develops novel E3 ligases beyond CRBN, expanding the range of targets and addressing resistance mechanisms.

Pipeline and clinical programs

• Fully-owned pipeline includes CT-01 (GSPTI & NEK7) for HCC and lung cancer, CT-03 (MCL-1) for liquid and solid tumors, CT-02B/S (NEK7) for neuroinflammation and autoimmunity, and CT-05 (PKCE) for autoimmune disorders.

• CT-01 is a dual GSPTI & NEK7 degrader in Phase 1 for HCC, with dose escalation initiated in May 2025 and potential for synergy with everolimus.

• CT-03 is a first-in-class MCL-1 degrader in IND-enabling studies, showing high efficacy and safety in preclinical models.

• CT-02S/B NEK7 degraders show efficacy in autoimmune and neurodegenerative disease models, with high selectivity and safety demonstrated in vitro and in vivo.

• CT-05 targets PKCE, an undrugged kinase implicated in multiple autoimmune and inflammatory diseases, with early-stage lead optimization underway.